Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy

Journal of Nanobiotechnology

Volumn 10, Issue , 2012, Pages

  Ranjan, Amalendu P ^a   Mukerjee, Anindita ^a   Helson, Lawrence ^b   Vishwanatha, Jamboor K ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b SignPath Pharmaceuticals Inc   (United States)

Author keywords

Cancer; Central composite design (CCD); Curcumin C3 complex; Optimization; PLGA nanoparticles; Response surface methodology (RSM); Scale up

Indexed keywords

CANCER; CENTRAL COMPOSITE DESIGNS; CURCUMIN; PLGA NANOPARTICLES; RESPONSE SURFACE METHODOLOGY; SCALE-UP;

BIOCHEMISTRY; COPOLYMERS; DRUG PRODUCTS; EMULSIFICATION; ENCAPSULATION; LACTIC ACID; ONCOLOGY; OPTIMIZATION; PARTICLE SIZE; PHARMACOKINETICS; STERILIZATION (CLEANING);

NANOPARTICLES;

CURCUMIN; POLYGLACTIN;

AREA UNDER THE CURVE; ARTICLE; CENTRAL COMPOSITE DESIGN; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STABILITY; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PROCESS OPTIMIZATION; REPONSE SURFACE METHODOLOGY; SCALE UP;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CURCUMIN; DRUG CARRIERS; DRUG STABILITY; HUMANS; LACTIC ACID; MALE; MICROSCOPY, CONFOCAL; MODELS, CHEMICAL; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RESEARCH DESIGN; TRANSCRIPTION FACTOR RELA;

RATTUS;

EID: 84865558125     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-10-38     Document Type: Article

References (46)

1. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010, 17:190-197. 10.2174/092986710790149738, 20214562.
2. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today 2012, 17(1-2):71-80.
3. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10(20):6847-6854. 10.1158/1078-0432.CCR-04-0744, 15501961.
4. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21(4B):2895-2900.
5. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 2002, 21(3):251-262. 10.1016/S0945-053X(02)00007-0, 12009331.
6. Kurien BT, Scofield RH. Increasing aqueous solubility of curcumin for improving bioavailability. Trends Pharmacol Sci 2009, 30(7):334-335. 10.1016/j.tips.2009.04.005, 19523694.
7. Kurien BT, Scofield RH. Heat-Solubilized Curcumin Should Be Considered in Clinical Trials for Increasing Bioavailability. Clin Cancer Res 2009, 15(2):747-747. 2693878, 19147784.
8. Anand PP. Bioavailability of Curcumin: Problems and Promises. Mol Pharm 2007, 4(6):807-818. 10.1021/mp700113r, 17999464.
9. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009, 37(3-4):223-230.
10. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnol 2007, 5:3.
11. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007, 330(1-2):155-163.
12. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007, 337(1-2):299-306.
13. Yadav VR, Suresh S, Devi K, Yadav S. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease. J Pharm Pharmacol 2009, 61(3):311-321.
14. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009, 29(10):3867-3875.
15. Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, He J, Alb A, John V, Pochampally R. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine 2012, 8(4):440-451. 10.1016/j.nano.2011.07.011, 21839055.
16. Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab 2012, 13(1):120-128. 10.2174/138920012798356952, 21892919.
17. Chang L, Wu S, Tsai J, Yu T, Tsai T. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery. Int J Pharm 2009, 376(1-2):195-203.
18. Murakami H, Kawashima Y, Niwa T, Hino T, Takeuchi H, Kobayashi M. Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(-lactide-co-glycolide) nanoparticle. Int J Pharm 1997, 149(1):43-49.
19. Li L, Zhao X, Yang C, Hu H, Qiao M, Chen D. Preparation and optimization of doxorubicin-loaded albumin nanoparticles using response surface methodology. Drug Dev Ind Pharm 2011, 37(10):1170-1180. 10.3109/03639045.2011.563781, 21449822.
20. Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, Peng X. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine 2011, 6:683-692. 3084315, 21556343.
21. Woitiski CB, Veiga F, Ribeiro A, Neufeld R. Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. Eur J Pharm Biopharm 2009, 73(1):25-33. 10.1016/j.ejpb.2009.06.002, 19508892.
22. Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, Shi Y. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 2010, 197(1-2):120-128.
23. Box GEP. Multi-factor experimental designs for exploring response surfaces. Ann Mathematical Stat 1957, 28(1):195.
24. Derringer G, Suich R. Simultaneous optimization of several response variables. J Qual Technol 1980, 12(4):214-219.
25. Ranjan AP, Zeglam K, Mukerjee A, Thamake S, Vishwanatha JK. A sustained release formulation of chitosan modified PLCL:poloxamer blend nanoparticles loaded with optical agent for animal imaging. Nanotechnology 2011, 22(29):295104. 10.1088/0957-4484/22/29/295104, 21693801.
26. Karasulu E, Yesim Karasulu H, Ertan G, Kirilmaz L, Guneri T. Extended release lipophilic indomethacin microspheres: formulation factors and mathematical equations fitted drug release rates. Eur J Pharm Sci 2003, 19(2-3):99-104.
27. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001, 13(2):123-133. 10.1016/S0928-0987(01)00095-1, 11297896.
28. Li J, Jiang Y, Wen J, Fan G, Wu Y, Zhang C. A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome. Biomed Chromatogr 2009, 23(11):1201-1207. 10.1002/bmc.1244, 19488971.
29. Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, Garcia ML. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 2011, 22(4):045101. 10.1088/0957-4484/22/4/045101, 21169662.
30. Duan Y, Xu S, Wang Q, Liu J, Zhang Z. Optimization of preparation of DHAQ-loaded PEG-PLGA-PEG nonaparticles using central composite design. J Mater Sci Mater Med 2006, 17(6):559-563. 10.1007/s10856-006-8940-4, 16691355.
31. Wu XG, Li G, Gao YL. Optimization of the preparation of nalmefene-loaded sustained-release microspheres using central composite design. Chem Pharm Bull 2006, 54:977. 10.1248/cpb.54.977, 16819215.
32. Araujo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm 2010, 393(1-2):167-175.
33. Kassama LS, Shi J, Mittal GS. Optimization of supercritical fluid extraction of lycopene from tomato skin with central composite rotatable design model. Sep Purif Technol 2008, 60(3):278-284.
34. Liu Y, Zhang P, Feng N, Zhang X, Wu S, Zhao J. Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin. Int J Pharm 2009, 365(1-2):136-142.
35. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008, 68(3):513-525.
36. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (,-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Controlled Release 2002, 82(1):105-114.
37. DeMerlis CC, Schoneker DR. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol 2003, 41(3):319-326. 10.1016/S0278-6915(02)00258-2, 12504164.
38. Sun M, Gao Y, Guo C, Cao F, Song Z, Xi Y, Yu A, Li A, Zhai G. Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticle. J Nanopart Res 2010, 12:3111-3122.
39. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010, 31(25):6597-6611. 10.1016/j.biomaterials.2010.04.062, 20553984.
40. Liu Q, Loo WTY, Sze SCW, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFκB, cyclinD and MMP-1 transcription. Phytomedicine 2009, 16(10):916-922. 10.1016/j.phymed.2009.04.008, 19524420.
41. Ma Z, Shayeganpour A, Brocks DR, Lavasanifar A, Samuel J. High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr 2007, 21(5):546-552. 10.1002/bmc.795, 17340565.
42. Duan J, Zhang Y, Han S, Chen Y, Li B, Liao M, Chen W, Deng X, Zhao J, Huang B. Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 2010, 400(1-2):211-220.
43. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev 2006, 58(15):1688-1713. 10.1016/j.addr.2006.09.017, 17118485.
44. Holzer M, Vogel V, Mäntele W, Schwartz D, Haase W, Langer K. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm 2009, 72(2):428-437. 10.1016/j.ejpb.2009.02.002, 19462479.
45. Bozdag S, Dillen K, Vandervoort J, Ludwig A. The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly(D, L-lactide-glycolide) nanoparticles. J Pharm Pharmacol 2005, 57(6):699-707.
46. Memisoglu-Bilensoy E, Hincal AA. Sterile, injectable cyclodextrin nanoparticles: effects of gamma irradiation and autoclaving. Int J Pharm 2006, 311(1-2):203-208.